ACE2 and COVID-19: SARS‐CoV‐2 enters the host via angiotensin‐converting enzyme 2 (ACE2), which is also expressed in pancreatic beta cells, thus providing a pathway for the virus to enter and destroy the islets and resulting in defective insulin production and hyperglycemia in COVID‐19 patients12, 17, 18 SARS CoV‐2 infection leads to increased release of inflammatory factors, which causes insulin resistance and thus contributes to elevated blood glucose.7, 17, 18